Santen Pharmaceutical Co Ltd (OTCPK:SNPHY)
$ 9.928 -1.002 (-9.17%) Market Cap: 3.75 Bil Enterprise Value: 3.20 Bil PE Ratio: 22.08 PB Ratio: 2.01 GF Score: 80/100

Santen Pharmaceutical Co Ltd R&D Day 2 Transcript

Sep 06, 2019 / 04:00AM GMT
Release Date Price: $16.83 (-0.36%)
Takeshi Matsugi
Santen Pharmaceutical Co., Ltd. - Head of R&D Strategic Operations

[Interpreted] We would like to begin R&D Day 2: The Future of Santen R&D.

Thank you very much for attending today despite your very busy schedule. First, let me introduce our attendees today. Satoshi Suzuki, Senior Corporate Officer and Head of Corporate Development Division and China Business; Naveed Shams, Senior Corporate Officer and Chief Scientific Officer, Head of Global R&D, Naveed Shams; Senior Vice President, Head of Biomedical and Strategy and Research, Reza Haque; Corporate Officer, Head of Pharmaceutics & Pharmacology Representative Asia R&D, Kenji Morishima; Senior Vice President, Head of Product Development, Representative, U.S. R&D, Peter Sallstig; and Shigeo Taniuchi, our President and Chief Operating Officer, is attending a conference in China. Therefore, he is not able to be here in person, but he will join us by phone to say a few words of greetings later.

My name is Takashi Matsugi, Head of R&D Strategic Operations. I will be moderating this meeting

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot